Trifluridine–tipiracil with bevacizumab is NICE  recommended, within its marketing authorisation, for treating metastatic colorectal cancer in adults who have had 2 lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, antivascular endothelial growth factor or anti-epidermal growth factor receptor treatments).

在其上市许可范围内，NICE推荐三氟尿苷-替吡拉西联合贝伐单抗治疗成人转移性结直肠癌，这些患者有2种治疗方案（包括基于氟嘧啶，奥沙利铂和伊立替康的化疗，抗血管内皮生长因子或抗表皮生长因子受体治疗）。

Trifluridine–tipiracil with bevacizumab is only recommended if the company provides trifluridine–tipiracil according to the commercial arrangement.

只有当公司根据商业安排提供三氟尿苷-替吡拉西时，才推荐使用三氟尿苷-替吡拉西联合贝伐单抗。

Why the committee made this recommendation; Standard treatment for metastatic colorectal cancer after 2 lines of treatment includes trifluridine–tipiracil alone or regorafenib. The results of a clinical trial show that, compared with trifluridine–tipiracil alone, trifluridine–tipiracil plus bevacizumab increases how long people have before their cancer gets worse and how long they live.

委员会为什么提出这一建议；两种治疗方案后转移性结直肠癌的标准治疗方法包括单独使用三氟尿苷-替吡拉西或瑞格非尼。。

The results of an indirect comparison also suggest that trifluridine–tipiracil plus bevacizumab increases how long people have before their cancer gets worse and how long they live compared with regorafenib. When considering the condition's severity, and its effect on quality and length of life, the most likely cost-effectiveness estimates are within the range that NICE normally considers an acceptable use of NHS resources.

间接比较的结果还表明，与瑞格非尼相比，三氟尿苷-替吡拉西联合贝伐单抗可增加癌症恶化的时间和寿命。当考虑到病情的严重程度及其对质量和寿命的影响时，最有可能的成本效益估计值在NICE通常认为可以接受的NHS资源使用范围内。

So, trifluridine–tipiracil plus bevacizumab is recommended..

因此，建议使用三氟啶替吡拉西联合贝伐单抗。

Condition: Colorectal Cancer

病情：结直肠癌

Type: drug

类型：药物